Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of SKLB1028 versus salvage chemotherapy in relapsed/refractory FLT3-mutated acute myeloid leukemia
CTR20202269Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruserontinib in acute myeloid leukemia (AML), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Mar 2021; status: completed.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20202269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202269.